European Archives - Page 216 of 1271 - European Medical Journal

UDCA May Reduce Need for Surgery in Gallstone Management After Bariatric Surgery

Ursodeoxycholic acid (UDCA) may provide a safe and effective alternative to surgery for dissolving gallstones in patients who have undergone sleeve gastrectomy, according to a new study. Gallstones dissolved in 60% of patients treated with UDCA, with fewer hospitalisations and mild side effects.

ESGO 2025 Insights: An Interview with Bradley Monk

Bradley Monk discusses ground-breaking innovations and the future of gynaecologic oncology from ESGO 2025.

Investigating Probiotics for Managing Atopic Dermatitis in Infants

Recent research highlights the role of gut microbiota in atopic dermatitis pathogenesis.

EMJ Dermatology 13 [Supplement 1] 2025

Nemolizumab is an anti-IL-31Rα monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and…

Nemolizumab in Atopic Dermatitis

Nemolizumab is an anti-IL-31Rα monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and…

Butter vs. Plant-Based Oils: Groundbreaking Study Reveals Butter Linked to Higher Death Rates

Butter linked to higher mortality; plant-based oils reduce death risks. Study urges dietary swaps for long-term health.

Cartoon brain on green background

Phase 2 trial begins for psychedelic-based depression treatment

A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.

Niraparib Shows Promise in Ovarian Cancer: ESGO 2025

The MITO 40 study, presented at ESGO 2025, highlights promising results for Niraparib as a maintenance treatment in ovarian cancer patients with no residual disease post-surgery.

Updated ATHENA-MONO Data Confirms Rucaparib Benefits: ESGO 2025

Rucaparib showed longer progression-free survival, chemotherapy-free interval, and time to first subsequent treatment in advanced ovarian cancer patients, according to updated results from the ATHENA-MONO study.

Treatment Advances in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

The primary treatment for intermediate and high-risk NMIBC includes transurethral resection of the bladder tumour.